Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what steps his Department is taking to ensure the safety of the HPV vaccination.
Answered by Baroness Blackwood of North Oxford
As with all vaccines and medicines, the Medicines and Healthcare products Regulatory Agency (MHRA) is monitoring the safety of human papillomavirus (HPV) vaccine in the United Kingdom. The MHRA takes advice from the Government's independent expert advisory body, the Commission on Human Medicines, when evaluating the risks and benefits of medicines and vaccines. The MHRA's current assessment is that available evidence does not support a causal link between the HPV vaccination and development of chronic illnesses, and that the benefits in protecting against cervical cancer and other HPV-related disease outweigh the possible known side effects of the vaccines.
Separately, the Joint Committee on Vaccination and Immunisation (JCVI) carried out reviews of HPV vaccine safety in June 2015 and also advised that available evidence does not support a causal link between the HPV vaccine and development of chronic illnesses. JCVI concluded that it had no concerns about the safety of the HPV vaccine and strongly supported continued use of the vaccine to prevent infection with HPV and reduce cases of cervical cancer and other HPV associated cancers.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what proportion of the total NHS budget was spent on translation services in 2015-16; and how much was spent on translation services in each NHS (a) trust and (b) foundation trust in 2015-16.
Answered by Alistair Burt
This information is not held centrally.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, on average how many patients died in A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in the last 12 months for which data is available.
Answered by Jane Ellison
The average (mean) number of patients who died in accident and emergency (A&E) and who attended A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in 2013-14 is shown in the following table. These figures are taken from the Health and Social Care Information Centre’s Hospital Episode Statistics (HES). Final data for 2014-15 will be published on 28 January 2016.
Weekday | Average (mean) deaths in A&E department | Average (mean) attendances at A&E |
Monday | 59.3 | 55,212.7 |
Tuesday | 54.0 | 49,660.8 |
Wednesday | 56.0 | 48,667.0 |
Thursday | 53.7 | 48,600.3 |
Friday | 55.6 | 47,932.3 |
Saturday | 55.8 | 48,614.6 |
Sunday | 57.1 | 50,202.9 |
Source: (HES), Health and Social Care Information Centre
Notes:
1. The table shows the mean of A&E attendances, and the mean of A&E attendances where the patient died in the department, by weekday for 2013-14. The HES A&E database is recorded at attendance level, not patient level.
2. The data cannot be described as an average number of people as the same person may have had more than one A&E attendance within the time period presented.
3. The data excludes planned follow-up attendances.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, on average, how many patients were admitted to A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in the last 12 months for which data is available.
Answered by Jane Ellison
The average (mean) number of patients who died in accident and emergency (A&E) and who attended A&E on a (a) Monday, (b) Tuesday, (c) Wednesday, (d) Thursday, (e) Friday, (f) Saturday and (g) Sunday in 2013-14 is shown in the following table. These figures are taken from the Health and Social Care Information Centre’s Hospital Episode Statistics (HES). Final data for 2014-15 will be published on 28 January 2016.
Weekday | Average (mean) deaths in A&E department | Average (mean) attendances at A&E |
Monday | 59.3 | 55,212.7 |
Tuesday | 54.0 | 49,660.8 |
Wednesday | 56.0 | 48,667.0 |
Thursday | 53.7 | 48,600.3 |
Friday | 55.6 | 47,932.3 |
Saturday | 55.8 | 48,614.6 |
Sunday | 57.1 | 50,202.9 |
Source: (HES), Health and Social Care Information Centre
Notes:
1. The table shows the mean of A&E attendances, and the mean of A&E attendances where the patient died in the department, by weekday for 2013-14. The HES A&E database is recorded at attendance level, not patient level.
2. The data cannot be described as an average number of people as the same person may have had more than one A&E attendance within the time period presented.
3. The data excludes planned follow-up attendances.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the (a) target, (b) average and (c) longest time taken to approve individual funding requests are for diseases in the last 12 months for which data is available.
Answered by George Freeman
NHS England has advised that its standard operating procedures published target to process individual funding requests is 40 days. This is for all cases no matter what their outcome.
In the last 12 months for which data is available, NHS England has advised that the average approval time was 20 days, with the longest approval time being 66 days and the shortest being two days.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what information his Department holds on the efficacy of anakinra for patients diagnosed with idiopathic recurrent pericarditis; and what the (a) target, (b) average and (c) longest time taken to approve that drug for use was in the last 12 months for which data is available.
Answered by George Freeman
The Medicines and Healthcare products Regulatory Agency (MHRA) does not hold information concerning the efficacy of anakinra for patients diagnosed with idiopathic recurrent pericarditis.
Kineret, containing the active substance anakinra, was approved by the European Medicines Agency (EMA) in 2002 for the treatment of rheumatoid arthritis in adults. The licence was extended to include treatment of Cryopyrin-Associated Periodic Syndromes. Anakinra is not licensed to treat idiopathic recurrent pericarditis.
The EMA is required to issue an opinion on applications for new indications within 90 days of receipt of a valid application. This period will be extended if it needs to request supplementary information from the applicant. The applicant will be requested to provide supplementary information within one month, although this may be extended to two months. The assessment of any supplementary information by EMA should be completed within 60 days. The European Commission is required to amend the marketing authorisation within two months of the EMA opinion.
The MHRA does not hold information on average and longest time for approval of variations by EMA.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what account was taken of the financial costs and workforce implications of maintaining high-risk general surgery at University Hospital South Manchester to support the provision of tertiary services for the purposes of the Decision Making Business Case under the Healthier Together programme; and whether those factors were included in the financial modelling for options 4.3 and 4.4 of that programme.
Answered by Ben Gummer
The Government is clear the reconfiguration of front line health services is a matter for the local National Health Service.
Principles for service change are enshrined in the four reconfiguration tests set down to the NHS in 2010. All local reconfiguration plans should demonstrate: support from GP commissioners; strengthened public and patient engagements; clarity on the clinical evidence base; and support for patient choice.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what provision his Department plans to make under the Healthier Together reforms for patients in the North West of England with severe and complex cardiac disease who need tertiary cardiorespiratory services.
Answered by Ben Gummer
The Government is clear the reconfiguration of front line health services is a matter for the local National Health Service.
Principles for service change are enshrined in the four reconfiguration tests set down to the NHS in 2010. All local reconfiguration plans should demonstrate: support from GP commissioners; strengthened public and patient engagements; clarity on the clinical evidence base; and support for patient choice.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the hospital mortality rate was for each of the Greater Manchester acute hospital trusts in the most recent year for which figures are available.
Answered by Ben Gummer
The data requested on hospital mortality rates is not available centrally.
Asked by: Graham Brady (Conservative - Altrincham and Sale West)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what analysis his Department and NHS England have carried out to determine what standard of high-risk general surgery a site should be providing in order to be an appropriate site for carrying out (a) complex cardiac surgery and (b) other tertiary services.
Answered by Ben Gummer
The standards a site should be providing in order to be an appropriate site for carrying out complex cardiac surgery and other tertiary services are already set out by the professional bodies (Royal College of Surgeons, Society of Cardiothoracic Surgeons of Great Britain and Ireland) and NHS England Specialised Services service specifications.